Table 3.

Patient characteristics in [¹³¹I]MIBG.

Patient	Age	Gender	Primary location	Mutation	Previous treatments	Previous functional image	Metastases location	Cycles	Side effects	Biochemical response	Radiological response	Clinical response	Survival	PFS	Subsequent treatments
1	5	M	Abdominal PGL	–	131I-MIBG 2 cycles in another center	MIBG+, FDG+	Lymph nodes, bone	1	No	CR	PR	CR	77 months	77 months	No
2	36	M	Pelvic PGL	SDHB	Non specified chemotherapy. Bone thermoablation	MIBG++, FDG++	Lung, lymph nodes, bone, liver, abdominal implants	2	No	–	–	SD 6 months, Loss of clinical follow-up	50 months	6 months	–
3	65	M	Left PHEO	Sporadic	No	MIBG+, FDG+	Lung, lymph nodes	1	No	SD	SD 20 months, afterwards PD	SD 20 months, afterwards PD	49 months	20	CVD
4	77	F	Left PHEO	–	CVD	SRS+/−, MIBG++	Lung, lymph nodes, abdominal implants	1	No	PD	PD	PD	3 months, exitus	0	–
5	27	M	Abdominal PGL	SDHB	CVD, bone cementation, SSA, pelvic RT, TMZ	SRS+, MIBG+	Bone, lymph nodes	1	Hypertensive crisis	PD	SD 3 months, afterwards PD	SD 6 months, afterwards PD	32 months, exitus	0	PRRT 4 cycles, CVD
6	43	F	Right PHEO	Sporadic	SSA, abdominal implant resection	SRS+, MIBG++	Lymph nodes, bone, abdominal implants	1	Hypertensive crisis with Valsalva maneuver	PR 21 months, afterwards PD	SD 21 months, afterwards PD	SD 21 months, afterwards PD	31 months	21 months	PRRT 4 cycles
7	63	F	Right PHEO	Sporadic	Liver metastasectomy nephrectomy, RT	SRS−, MIBG+	Lymph nodes, bone, liver, kidney	1	No	PR	SD	SD	24 months	24 months	No
8	48	M	Left PHEO	Sporadic	CVD, CAPTEM a , SSA	Gallium(PET/MRI)+, MIBG+ DOPA++, FDG++	Lung, Lymph nodes, abdominal implants, spleen	1	Hematologic grade 2 toxicity, GI	–	–	PD	3 months	0 months	No

^aCapecitabine and temozolomide.

++, very intense uptake; +, intense uptake; +/−, low or heterogeneous uptake; −, very low or absent uptake.